Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2015-11-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2015.09.032PMID 26428869
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of N-sulfonyl-7-azaindoline derivatives as potent, orally available and selective M(4) muscarinic acetylcholine receptor agonists.

  2014cited by this paper
• Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.

  2014cited by this paper
• Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M(1) and M(4) muscarinic acetylcholine receptors agonists.

  2013cited by this paper
• Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.

  2013cited by this paper
• Experimental and computational study of intermolecular migration of N,N-dimethylcarbamoyl group from N(7) to N(1) on a 7-azaindoline derivative

  2013cited by this paper
• Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

  2012cited by this paper
• Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects

  2012cited by this paper
• An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine

  2012cited by this paper
• Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.

  2011cited by this paper
• Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

  2010cited by this paper
• Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

  2010cited by this paper
• Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.

  2009cited by this paper
• A scalable synthesis of an azabicyclooctanyl derivative, a novel DPP-4 inhibitor.

  2008cited by this paper
• Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

  2008cited by this paper
• Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

  2008cited by this paper
• Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats

  2008cited by this paper
• Towards a muscarinic hypothesis of schizophrenia

  2007cited by this paper
• Muscarinic receptor subtype pharmacology and physiology.

  2005cited by this paper
• N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity

  2003cited by this paper
• Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1 Muscarinic Acetylcholine Receptor

  2001cited by this paper
• International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

  1998cited by this paper
• Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.

  1997cited by this paper
• Molecular biology of muscarinic acetylcholine receptors.

  1996cited by this paper
• Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain.

  1993cited by this paper
• Muscarinic receptor subtypes.

  1990cited by this paper

• The Prosperity and Adversity of M4 Muscarinic Acetylcholine Receptor Activators in the Treatment of Neuropsychiatric Disorders.

  2025cites this paper
• A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse

  2025cites this paper
• Transaminases Provide Key Chiral Building Blocks for the Synthesis of Selective M1/M4 Agonists.

  2023cites this paper
• Synthesis, molecular docking, and cytotoxicity of quinazolinone and dihydroquinazolinone derivatives as cytotoxic agents

  2022cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022cites this paper
• Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases

  2021influential citation
• Biomimetic Asymmetric Reduction of Quinazolinones with Chiral and Regenerable NAD (P)H Models

  2020cites this paper
• Synthesis of substituted 3,4-dihydroquinazolinones via a metal free Leuckart–Wallach type reaction

  2020cites this paper
• 2,3-Dihydroquinazolin-4(1H)-one as a privileged scaffold in drug design

  2018cites this paper
• An efficient synthesis of the piperidinyl dihydroquinazolinone (PDQ) fragment of olcegepant

  2018cites this paper
• Discovery and Development of Muscarinic Acetylcholine M4 Activators as Promising Therapeutic Agents for CNS Diseases.

  2018cites this paper
• Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.

  2018cites this paper
• Synthesis and computational analysis of conformationally restricted [3.2.2]- and [3.2.1]-3-azabicyclic diamines

  2017cites this paper
• Process Development for the Synthesis of a Selective M1 and M4 Muscarinic Acetylcholine Receptors Agonist

  2017cites this paper
• Synthetic strategy with representation on mechanistic pathway for the therapeutic applications of dihydroquinazolinones.

  2016cites this paper